Drug Topics
DECEMBER 21, 2023
A Saturday Night Live skit has been met with criticism for its caricatured portrayal of patients with sickle cell disease, especially as the performance cast a dark shadow over the recent breakthrough FDA treatment approvals.
Pharmacy Times
DECEMBER 21, 2023
Pharmacists play a vital role in HIV care by addressing social determinants of health, managing complex HIV medication regimens, and providing comprehensive patient counseling.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 21, 2023
Odds are, you’ve gotten at least one of the unnerving letters in your mailbox this year: “We’re writing to inform you of a cybersecurity incident,” it might start. It’s the standard notice many health care organizations are required to provide when your protected health information gets exposed — and in 2023, data leaks, hacks, and mishandling led more of them to be delivered than ever before.
Pharmacy Times
DECEMBER 21, 2023
Overtime, children can outgrow food allergies, like milk and eggs—however, children with private insurance are more likely to outgrow allergies than those with public insurance.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 21, 2023
WASHINGTON — Medical marijuana companies sell medicine, just like pharmaceutical companies. But they’re not playing by the same rules — and that’s putting patients at risk. Several of the largest medical marijuana companies, like Trulieve, Curaleaf, and Verano, are advertising their products as treatments not just for muscle aches, but for major medical conditions like cancer and depression, without evidence to back up those claims.
Fierce Healthcare
DECEMBER 21, 2023
A new policy from Blue Cross Blue Shield Massachusetts, starting Jan. | Some patients needing a colonoscopy in Massachusetts won't be covered for monitored anesthesia care, or MAC, starting Jan. 1. Blue Cross Blue Shield Massachusetts is standing by the policy, which will save the insurer money but require the patient to remain awake for the operation.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
DECEMBER 21, 2023
The nonprofit pharmaceutical company plans to begin fulfilling orders for RiVive more broadly in early 2023 and will make it available across the US for free of charge or at a low breakeven cost.
STAT
DECEMBER 21, 2023
The past year has brought huge changes in medicine and science — from innovations like the first curative treatment for sickle cell to legislative restrictions on abortion access. But at the center of all these stories are the people they impact: scientists, doctors, patients, and families. As we look back at 2023 in photographs, the faces of so many stand out: investors and researchers moving their industries forward, a man working to escape the cycle of addiction, a physi
Fierce Pharma
DECEMBER 21, 2023
As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their CRISPR-based gene-editing therapy Casgevy, one doctor who treats sickle cell disease patients is already | As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their world-first CRISPR-based gene therapy Casgevy, one doctor who treats sickle cell disease patients is already seeing strong demand.
STAT
DECEMBER 21, 2023
WASHINGTON — Sometime next year drug and medical device companies will have to tell the Food and Drug Administration how they plan to include people of color in clinical trials. But planning isn’t the same as doing, the industry’s track record isn’t great, and it’s not clear whether the FDA will twist arms, experts told STAT.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
DECEMBER 21, 2023
Tune in to this episode of Public Health Matters for a captivating exploration of global public health through the lens of a pharmacist and traveler.
STAT
DECEMBER 21, 2023
To ring the register, a pharmaceutical company may create a patent thicket , which involves filing dozens of patents that, in some cases, add little value to their medicines but extend precious monopolies. And one crucial, but little-known tool for making this happen is something called a terminal disclaimer. In short, a terminal disclaimer is a stipulation provided to the U.S.
Fierce Pharma
DECEMBER 21, 2023
Big Pharma companies have often talked about the major opportunities that await in China. | Big Pharma companies have often talked about the major opportunities that await in China. But as price cuts play out and internal priorities shift, multinational companies are reworking their business models in the country.
STAT
DECEMBER 21, 2023
The Food and Drug Administration approved a novel medicine for a rare and devastating nerve disease Thursday, clearing a treatment that promises to be more convenient than available therapies. The drug, from partners AstraZeneca and Ionis Pharmaceuticals, is a monthly injection for a genetic disorder called ATTR-PN, in which a buildup of toxic bodily proteins progressively damages patients’ peripheral nerves.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
DECEMBER 21, 2023
Wendy Crouse, DVM, an independent house call veterinarian with Heal House Call Veterinarian, sat down with Drug Topics to discuss how the adoption of e-prescribing has transformed her practice.
Fierce Healthcare
DECEMBER 21, 2023
Physician pay and workforce issues were top of mind for Fierce Healthcare readers in 2023. | Physician pay and workforce issues were top of mind for Fierce Healthcare readers in 2023. The biggest stories in 2023, determined by you, the reader, include major hospital mergers, changes to the Medicare Advantage program, Amazon's latest healthcare move, and of course, generative AI.
Pharmacy Times
DECEMBER 21, 2023
Budesonide is now the first fully FDA-approved treatment for primary immunoglobulin A nephropathy, based on measures of kidney function.
STAT
DECEMBER 21, 2023
Chronic disease is, by its very definition, omnipresent. But changes year to year have the potential to make certain conditions into flaming-red targets for researchers and drugmakers. This year was one for obesity, marked by new — and for the first time, highly effective — weight loss drugs that demonstrated other health benefits. But whether that wave of interest will persist into the new year, or transfer to some other condition — maybe some liver diseases that are
Pharmacy Times
DECEMBER 21, 2023
Comprehensive medication reviews and drug interaction assessments are examples of clinical interventions
STAT
DECEMBER 21, 2023
What does it mean to a bad CEO? Can biotech endure another election year? And can you go to too many J.P. Morgan parties? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store for the drug industry.
Fierce Pharma
DECEMBER 21, 2023
Ionis Pharmaceuticals and AstraZeneca are wrapping up the year with a much-anticipated present from the FDA: an approval for the companies’ transthyretin amyloidosis (ATTR) drug Wainua. | The approval in hereditary transthyretin-mediated amyloid polyneuropathy, which affects around 40,000 to 50,000 patients globally, sets the stage for a potential label expansion down the line to treat the broader transthyretin amyloid cardiomyopathy patient population.
Pharmacy Times
DECEMBER 21, 2023
These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.
Fierce Pharma
DECEMBER 21, 2023
Two years ago, with a favorable ruling and a slap-on-the | A favorable ruling two years ago had Servier hoping that its decades-long litigation surrounding weight-loss pill Mediator was finally over. But an appeal from prosecutors now leaves the company facing a hefty penalty.
pharmaphorum
DECEMBER 21, 2023
An organisation representing the interests of patients with prostate cancer has published a manifesto ahead of the EU elections next year, calling for more screening for the disease in EU member states.
Fierce Pharma
DECEMBER 21, 2023
Along with a new CEO, BioMarin will head into 2024 with three new board directors and a new strategy review committee after settling with activist investor Elliott Investment Management. | Elliott Investment Management is one of BioMarin's largest investors with a stake worth more than $1 billion. The three new independent directors include a former Lilly exec and ImmunoGen's CEO.
Drug Topics
DECEMBER 21, 2023
An FDA-approval of Omalizumab would help reduce allergic reactions among 17 million people in the United States that have confirmed food allergies.
Pharmacy Times
DECEMBER 21, 2023
The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).
STAT
DECEMBER 21, 2023
Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. Good morning. Don’t miss Nicholas Florko’s jaw-dropping investigation into medical marijuana businesses marketing their products for cancer or depression with no regulatory oversight.
Pharmacy Times
DECEMBER 21, 2023
The study included data on ventilator-associated pneumonia and nonventilator hospital-acquired pneumonia, finding lower rates associated with daily toothbrushing.
The Checkup by Singlecare
DECEMBER 21, 2023
You may be used to shopping for the best price on electronics, furniture, or even your weekly tank of gas. But for many, searching for the best price on prescriptions is a new concept. In case you haven’t heard, SingleCare’s discount card can save you up to 80% on prescription costs. That may be hard to believe, but it’s true. The best part is it’s free to use—with no hidden fees.
STAT
DECEMBER 21, 2023
Good morning, everyone. Damian Garde here, filling in for Ed Silverman in a week customarily devoted to deciding just which tasks one can get away with putting off until next year. Here’s hoping you’re firmly on the downslope of doing actual work for the remainder of 2023. In the meantime, here are a few tidbits to start your day. And, as always, do let us know if you hear anything interesting out there.
The Checkup by Singlecare
DECEMBER 21, 2023
Metformin is a medication commonly used to treat people with Type 2 diabetes. It lowers your blood glucose levels, which reduces the risk of diabetic complications such as kidney disease and nerve damage. But since its FDA approval for the treatment of Type 2 diabetes back in 1994, metformin has emerged as something of a “miracle drug” thanks to its effectiveness in treating other common health conditions, like infertility, obesity , and heart disease.
STAT
DECEMBER 21, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with news of an averted activist challenge, biotech on late-night TV, and the latest deal in oncology’s hottest space.
pharmaphorum
DECEMBER 21, 2023
Sanofi ends development of CEACAM5-targeting ADC tusamitamab ravtansine after it fails a phase 3 trial in non-small cell lung cancer (NSCLC)
Expert insights. Personalized for you.
200 
Let's personalize your content